SE-Elocta-Personalised prophylaxis-4

Personalised prophylaxis for elevated protection^1,2

With ELOCTA, you can elevate protection by increasing time spent at higher FVIII levels vs SHL FVIII treatment.^2,3

ELOCTA offers the flexibility of personalisation while increasing time spent at elevated FVIII levels²

Adapted from Berntorp, et al. Haemophilia 2016.

By individualising prophylaxis with ELOCTA, you can offer:²

• Increased time spent at elevated FVIII levels without increasing weekly FVIII consumption vs SHL FVIII treatment
• Flexibility to adapt treatment around patients’ lifestyles

ELOCTA elevates FVIII levels and your patients' protection.^2,4,5

FVIII, factor VIII; IU, international units; SHL, standard half-life.

References

1. Srivastava A, et al. Haemophilia 2020;26(6):1–158. 2. Berntorp E, et al. Haemophilia 2016;22(3):389–396. 3. ELOCTA SmPC 01/2021. 4. Mahlangu J, et al. Blood 2014;123(3):317–325. 5. Quon D, et al. Haemophilia 2017;23(1):39–42.

PP-18595

nov, 2023

Personalised prophylaxis for elevated protection1,2

ELOCTA offers the flexibility of personalisation while increasing time spent at elevated FVIII levels2

ELOCTA elevates FVIII levels and your patients' protection.2,4,5

References

Personalised prophylaxis for elevated protection^1,2

ELOCTA offers the flexibility of personalisation while increasing time spent at elevated FVIII levels²

ELOCTA elevates FVIII levels and your patients' protection.^2,4,5